Critical Outcome T (NASDAQ:COTQF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Critical Outcome Technologies Inc. is a biopharmaceutical company which focuses on treatment of cancer. The company’s product consists of COTI-2, a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. Its artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Critical Outcome Technologies Inc. is based in London, Canada. “

Critical Outcome T (NASDAQ:COTQF) opened at 0.354 on Thursday. The firm has a 50 day moving average of $0.25 and a 200-day moving average of $0.22. The firm’s market cap is $52.80 million. Critical Outcome T has a 12 month low of $0.28 and a 12 month high of $0.69.

Your IP Address:

5 Day Chart for NASDAQ:COTQF

Get a free copy of the Zacks research report on Critical Outcome T (COTQF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Critical Outcome T Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Critical Outcome T and related companies with Analyst Ratings Network's FREE daily email newsletter.